Transdermal Delivery of Hypolipidemic Drugs : Overcoming Oral Therapy Limitations in Dyslipidemia Management
Author
Soumyaranjan Sahoo, Sritam Behera
Abstract
Dyslipidemia is a major risk factor for cardiovascular diseases, conventionally managed through oral hypolipidemic agents such as statins and fibrates. However, oral administration is often plagued by significant limitations, including poor oral bioavailability, extensive hepatic first-pass metabolism, and systemic side effects such as hepatotoxicity and myopathy. This research investigates the poten-tial of Transdermal Drug Delivery Systems (TDDS) to overcome these limitations. By formulating transdermal patches of selected hypolipidemic drugs, we achieved controlled systemic delivery, by-passed hepatic first-pass metabolism, and demonstrated enhanced relative bioavailability. Patient compliance is remarkably improved due to reduced dosing frequency and minimized gastrointesti-nal side effects.
Keywords
DyslipidemiaHypolipidemic drugsLipid-lowering therapy
Full Text:
References
[1]Ahad, A., Aqil, M., Kohli, K., Sultana, Y., & Mujeeb, M. (2010). Transdermal delivery of cardio-vascular agents. International Journal of Pharmaceutics, 392(1-2), 11-19.
[2]Alza, R., & Ruela, A. L. (2018). Current trends in transdermal delivery of statins. Journal of Controlled Release, 269, 134-142.
[3]Benson, H. A. (2005). Transdermal drug delivery: penetration enhancement techniques. Current Drug Delivery, 2(1), 23-33.
[4]Chen, Y., Wu, Q., & Zhang, Z. (2022). Ethosomal vesicles for deep dermal penetration of pravas-tatin. Biomaterials Science, 10(4), 950-960.
[5]Das, S., & Gupta, R. (2021). Nanoemulsion gel of fenofibrate for enhanced transdermal perme-ation. European Journal of Pharmaceutical Sciences, 158, 105658.
[6]Finnin, B. C., & Morgan, T. M. (1999). Transdermal penetration enhancers: applications, limita-tions, and potential. Journal of Pharmaceutical Sciences, 88(10), 955-958.
[7]Guy, R. H. (1996). Current status and future prospects of transdermal drug delivery. Pharmaceuti-cal Research, 13(12), 1765-1769.
[8]Jain, A. K., Thomas, P. N., & Panchagnula, R. (2002). Transdermal drug delivery of imipramine hydrochloride. I. Effect of terpenes. Journal of Controlled Release, 79(1-3), 93-101.
[9]Kalia, Y. N., Naik, A., Garrison, J., & Guy, R. H. (2004). Iontophoretic drug delivery. Advanced Drug Delivery Reviews, 56(5), 619-658.
[10]Kumar, L., & Singh, R. (2019). Matrix patch formulation of atorvastatin calcium. Drug Develop-ment and Industrial Pharmacy, 45(7), 1089-1098.
[11]Mitragotri, S., Blankschtein, D., & Langer, R. (1995). Ultrasound-mediated transdermal protein delivery. Science, 269(5225), 850-853.
[12]Naik, A., Kalia, Y. N., & Guy, R. H. (2000). Transdermal drug delivery: overcoming the skin’s barrier function. Pharmaceutical Science & Technology Today, 3(9), 318-326.
[13]Patel, D., Patel, N., & Parmar, M. (2018). Proniosomal gel of simvastatin for transdermal delivery.
Journal of Drug Targeting, 26(8), 682-691.
[14]Prausnitz, M. R., & Langer, R. (2008). Transdermal drug delivery. Nature Biotechnology, 26(11), 1261-1268.
[15]Sharma, S., Garg, A., & Narang, R. K. (2020). Microneedle array for transdermal delivery of rosuvastatin. AAPS PharmSciTech, 21(5), 184.
[16]Sinha, V. R., & Kaur, M. P. (2000). Permeation enhancers for transdermal drug delivery. Drug Development and Industrial Pharmacy, 26(11), 1131-1140.
[17]Thomas, B. J., & Finnin, B. C. (2004). The transdermal revolution. Drug Discovery Today, 9(16), 697-703.
[18]Trommer, H., & Neubert, R. H. (2006). Overcoming the stratum corneum: the modulation of skin penetration. Skin Pharmacology and Physiology, 19(2), 106-121.
[19]Vyas, S. P., & Khar, R. K. (2002). Targeted and Controlled Drug Delivery: Novel Carrier Systems. CBS Publishers & Distributors.
[20]Williams, A. C., & Barry, B. W. (2004). Penetration enhancers. Advanced Drug Delivery Reviews, 56(5), 603-618.